Investigation of the Efficacy of Metacognitive Training for Patients with Long-COVID - A Randomized Controlled Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00032218

Enrollment

Registered

2024-05-02

Start date

2023-09-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U09.9

Interventions

Group 1: Intervention group: patients receive 100 minutes of Metacognitive Training for 5-8 weeks (total: 8 group therapy sessions). The intervention of Metacognitive Training for Long-COVID is conduc

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Minimum age: 18 years Fluent in written and spoken German (to ensure understanding of diagnostic assessments and intervention). Confirmed COVID-19 infection in the past, proven by a laboratory test (U07.1!)

Exclusion criteria

Exclusion criteria: Acute suicidality Acute danger to others Acute self-harm Bipolar disorders (current or past episodes) Schizophrenic disorders (current or past episodes) Current psychotherapy, or unwillingness to pause current psychotherapy for the duration of the study (from T1 to T3) Consumption of addictive substances other than alcohol and nicotine in the past 3 months Presence of a addiction disease

Design outcomes

Primary

Measure	Time frame
Metacognitive skills (assessed by: Metacognition Questionnaire-30 (MCQ-30); Arndt et al., 2011). Long-COVID related quality of life (assessed by: Post Acute Covid-19 Quality of Life (PAC-19QoL); Jandhyala, 2021) Both primary endpoints will be assessed one week before the intervention starts (T0), one week after the intervention (T1), and at the follow-up time point (T2). In the control group, assessments will be conducted analogous to the intervention group.	—

Measure

Time frame

Metacognitive skills (assessed by: Metacognition Questionnaire-30 (MCQ-30); Arndt et al., 2011). Long-COVID related quality of life (assessed by: Post Acute Covid-19 Quality of Life (PAC-19QoL); Jandhyala, 2021) Both primary endpoints will be assessed one week before the intervention starts (T0), one week after the intervention (T1), and at the follow-up time point (T2). In the control group, assessments will be conducted analogous to the intervention group.

—

Secondary

Measure	Time frame
Depressive symptoms (assessed by: Beck Depression Inventory-II (BDI-II); Hautzinger, Keller & Kühner, 2006) Illness-related anxieties and depressions (assessed by: Hospital Anxiety and Depression Scale (HADS); Zigmond & Snaith, 1983) General quality of life (assessed by: World Health Organization - Quality of Life (WHOQOL-BREF); WHO Group, 1998) All three secondary endpoints will be assessed one week before the intervention starts (T0), one week after the intervention (T1), and at the follow-up time point (T2). In the control group, assessments will be conducted analogous to the intervention group.	—

Measure

Time frame

Depressive symptoms (assessed by: Beck Depression Inventory-II (BDI-II); Hautzinger, Keller & Kühner, 2006) Illness-related anxieties and depressions (assessed by: Hospital Anxiety and Depression Scale (HADS); Zigmond & Snaith, 1983) General quality of life (assessed by: World Health Organization - Quality of Life (WHOQOL-BREF); WHO Group, 1998) All three secondary endpoints will be assessed one week before the intervention starts (T0), one week after the intervention (T1), and at the follow-up time point (T2). In the control group, assessments will be conducted analogous to the intervention group.

—

Countries

Germany

Contacts

Public ContactMarius Scheiffele

Forschungssektion für angewandte Psychotherapie und Psychiatrie

marius.scheiffele@christophsbad.de004971616018748

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026